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Abstract Tumor necrosis factor receptor (TNFR)-associated
factor TRAF1 was first identified as a component of the TNFR2
signalling complex. Unlike the other members of the TRAF
family, TRAF1 lacks the N-terminal ring finger motif and has a
tissue specific expression. Here we demonstrate that expression
of TRAF1 is induced by TNF and the protein kinase C (PKC)
activator PMA, but not by interleukin-1 (IL-1). TNF-induced
upregulation of TRAF1 could be prevented by pretreatment of
the cells with the proteasome inhibitor MG-132, whereas the
PKC inhibitor Ro31-8220 was without effect. Interestingly,
overexpression of TRAF1 in HEK293T completely prevented
NF-UB activation induced by TNF, IL-1, or overexpression of
TRAF2 or TRAF6. These data suggest that inducible expression
of TRAF1 may serve a negative regulatory function in NF-UB
signalling pathways.
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1. Introduction
Tumor necrosis factor (TNF) is a proin£ammatory cyto-
kine that plays a key role in the generation of local and
systemic responses to infection, injury, and immunological
changes. TNF exerts its e¡ects through type 1 (TNFR1) or
type 2 (TNFR2) receptors, which belong to a large TNFR
superfamily that includes, among others, Fas (CD95), Wsl-1/
DR3, CD30, CD40, Ox-40, and the lymphotoxin-L receptor
[1]. The identi¢cation of several proteins that bind directly or
indirectly with the cytoplasmic domain of TNFR1 or TNFR2
has led to a better understanding of TNF signalling. Binding
of TNF to TNFR1 induces the recruitment of the signalling
protein TNFR1 associated death domain protein (TRADD
[2]), which serves as a platform to recruit at least three addi-
tional mediators: TNFR associated factor 2 (TRAF2 [3]),
receptor interacting protein (RIP [4]), and Fas-associated pro-
tein with death domain (FADD [5]). TNFR2 triggering results
in direct recruitment of TRAF2 and its relative TRAF1 [6].
To date, the TRAF family consists of six members that are
involved in intracellular signal transduction by several mem-
bers of the TNFR and interleukin-1 (IL-1) receptor superfam-
ily, including TNFR1, TNFR2, CD30, CD40, IL-1 receptor
and Toll-like receptor-4 (reviewed in [7]). Transfection experi-
ments implicated TRAF2 as a critical mediator of nuclear
factor UB (NF-UB [8]), c-jun N-terminal kinase (JNK [9])
and p38 mitogen activated protein kinase (MAPK [10,11])
activation by TNF. However, TRAF2 negative cells derived
from TRAF2 de¢cient mice are severely defective in TNF
induced JNK activation, whereas they still exhibit consider-
able, albeit slower, NF-UB activation [12]. The basis for this
discrepancy is not understood, but it has been suggested that
TRAF5 may substitute for TRAF2 in NF-UB activation [12].
TRAF6 is recruited to the IL-1 receptor and is crucial for
IL-1 induced activation of NF-UB, JNK and p38 MAPK
[13,14]. Si far the functions of TRAF1, 3 and 4 remain largely
unknown.
All TRAFs are composed of a highly conserved C-terminal
TRAF domain which mediates homotypic and heterotypic
TRAF-TRAF interactions, as well as the interaction with
other signalling proteins. In the case of TRAF2, these include
TRADD, TNFR2, RIP and the NF-UB inducing kinase NIK
(reviewed in [7]). A more variable N-terminal domain, which
contains a ring ¢nger and several zinc ¢nger motifs, is also
found in all TRAFs with the exception of TRAF1. Although
this N-terminal domain has been shown previously to be re-
quired for NF-UB activation [8,13,15], the underlying mecha-
nism is still unclear. In this report, we have focused on the
function of TRAF1, which di¡ers from the other TRAFs not
only at the structural level, but also by its tissue speci¢c ex-
pression [6]. We demonstrate that TRAF1 expression is highly
inducible by TNF and phorbol myristate acetate (PMA).
Moreover, overexpression of TRAF1 inhibits NF-UB activa-
tion induced by TNF and IL-1, suggesting that TNF induced
expression of TRAF1 provides a negative regulatory signal in
NF-UB signalling pathways.
2. Materials and methods
2.1. Cells and reagents
The HeLa cell line was a gift from Dr. H. Bujard (ZMBH, Heidel-
berg). HEK293T cells were a gift from Dr. M. Hall (Department of
Biochemistry, University of Birmingham). U937 cells were obtained
from Biogent (Belgium). PC60 cells stably expressing human TNFR1
and TNFR2 have been described previously [16]. HeLa and
HEK293T cells were cultured in Dulbecco’s modi¢ed Eagle’s medium,
U937 and PC60 cells were cultured in RPMI 1640. Media were sup-
plemented with 2 mM glutamine, 10% fetal calf serum, 106 U/l strep-
tomycin and 100 mg/l penicillin. 0.4 mM sodium pyruvate or 100 WM
L-mercaptoethanol were also added in the case of HEK293T or PC60,
respectively. MG-132 and Ro31-8220 were purchased from Calbio-
chem (La Jolla, CA), SB203580 was from Alexis Biochemicals (San
Diego, CA), PMA was from Sigma (St. Louis, MO). Immobilized
protein A on trisacryl was purchased from Pierce Chemical Co.
(Rockford, IL).
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2.2. Plasmids and antibodies
pRK5-TRAF1, pRK5-TRAF2, pRK5-TRAF6 were a generous gift
from Dr. D.V. Goeddel (Tularik, San Francisco, CA). pNFconluc,
which carries a luciferase gene under the control of a minimal pro-
moter preceded by three NF-UB binding sites, was provided by Dr. A.
Israel (Institut Pasteur, Paris). pUT651, a L-galactosidase expression
plasmid, was from Eurogentec (Seraing). PCDNA1-RIPE and
pCDNA1-TRADDE were prepared by cloning the PCR fragment
encoding RIP and TRADD in the pCDNA1 vector in frame with a
C-terminal E-tag. Anti-TRAF1 (H-132) and anti-TRAF2 (C-20) anti-
bodies were purchased from Santa Cruz Biotechnology (Santa Cruz,
CA); anti-E-tag antibodies were from Pharmacia Biotech (Uppsala).
2.3. Biological IL-6 assay
Secreted IL-6 was quantitated according to its growth stimulatory
e¡ect on 7TD1 cells [17]. Cell proliferation was assessed by colorimet-
ric determination of hexosaminidase levels [18].
2.4. NF-UB dependent reporter gene assay
HEK293T cells (3U105) were seeded in six well plates. The next day
cells were transfected by the calcium phosphate precipitation method
with 150 ng pUT651, 150 ng pNFconluc, 750 ng pRK5-TRAF1 and
250 ng empty vector, pRK5-TRAF2 or pRK5-TRAF6. Twenty hours
later, cells were trypsinized and one tenth of the cells coming from a
six well plate were transferred to a 24 well plate. One day later, cells
were either left untreated or treated for 6 h with 1000 IU/ml TNF,
7000 IU/ml IL-1 or 200 ng/ml PMA. Cell lysates were prepared and
NF-UB dependent luciferase (luc) gene expression was measured and
normalized for L-galactosidase (gal) activity as described previously
[19].
2.5. Western blot analysis of TRAF1 expression
Cell extracts were prepared in luciferase lysis bu¡er containing
25 mM Tris-phosphate pH 7.8, 2 mM DTT, 2 mM CDTA, 10%
glycerol, 1% Triton X-100, 1 mM PMSF, 0.1 mM aprotinin and
1 mM leupeptin. Insoluble material was removed by centrifugation
in an Eppendorf centrifuge. Samples containing equal amounts of
protein were separated on 10% SDS-polyacrylamide gels and blotted
onto nitrocellulose. Blots were blocked for 2 h in phosphate bu¡ered
saline supplemented with 3% non-fat dry milk and 0.2% Tween-20.
Blots were probed with a 1:500 dilution of anti-TRAF1 antibodies in
blocking bu¡er, followed by a 1:2000 dilution of donkey horseradish
peroxidase coupled anti-rabbit immunoglobulin. Bands were visual-
ized with enhanced chemiluminescence according to the protocol of
the manufacturer (Amersham Life Sciences, Amersham).
2.6. Coimmunoprecipitation
HEK293T cells (1.5U106) were seeded in 9 cm petri dishes. The
next day cells were transfected via the calcium phosphate precipitation
method with 1 Wg pRK5-TRAF2 and 1 Wg pCDNA1-TRADDE or
pCDNA1-RIPE, in the absence or presence of 3 Wg pRK5-TRAF1.
Empty vector was added to a total amount of 5 Wg DNA. Twenty-
four hours after transfection, cells were lysed in 20 mM Tris-HCl pH
7.5, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 mM PMSF,
0.1 mM aprotinin and 1 mM leupeptin, and lysates were incubated for
2 h with 2 Wg anti-E-tag antibody. Immune complexes were incubated
for 1 h with protein A-trisacryl beads, which were subsequently
washed four times with lysis bu¡er containing 700 mM NaCl. Copre-
cipitating proteins were separated by SDS-polyacrylamide gel electro-
phoresis and analyzed by Western blotting with a 1:1000 dilution of
TRAF-2 (C-20) antibodies, followed by a 1:2000 dilution of donkey
horseradish peroxidase coupled anti-rabbit immunoglobulin. Bands
were visualized with enhanced chemiluminescence according to the
protocol of the manufacturer (Amersham Life Sciences, Amersham).
3. Results
3.1. TRAF1 is inducible by TNF, but not by IL-1
Constitutive TRAF1 mRNA expression can only be de-
tected in limited tissues such as spleen, lung and testis [6].
Similarly, we could not detect any TRAF1 expression in var-
ious cell lines, including HeLa, PC60, and U937. Therefore,
we analyzed whether TRAF1 expression could be induced by
stimulation with TNF, IL-1 or the protein kinase C (PKC)
activator PMA. HeLa cells were treated with these agents for
18 h and analyzed for TRAF1 expression by Western blot
analysis with a TRAF1 speci¢c antiserum. Whereas TRAF1
could not be detected in unstimulated cells, TRAF1 was well
expressed in TNF and PMA stimulated HeLa cells (Fig. 1A).
A similar upregulation of TRAF1 by TNF and PMA could be
observed in U937 and PC60 cells (data not shown). Although
TNF induced gene expression is mostly mimicked by IL-1, to
our surprise the latter was not able to induce TRAF1 expres-
sion in HeLa cells. This di¡erential regulation is not due to a
general lack of IL-1 responsiveness of HeLa cells, because IL-
1 was still able to induce IL-6 gene expression in these cells
(Fig. 1B). Time kinetics revealed that the upregulation of
TRAF1 protein expression is detectable 4 h after the start
of TNF treatment, and lasts for at least up to 72 h (Fig. 2).
In contrast to TRAF1, the expression of other TNFR asso-
ciated proteins such as TRAF2, FADD, TRADD or RIP was
not modulated by TNF treatment (data not shown).
3.2. Signalling pathways involved in TRAF1 induction
TNF and PMA are both known activators of PKC [20,21].
Therefore, we investigated whether the upregulation of
TRAF1 by these stimuli was mediated by PKC. For this pur-
pose, we pretreated HeLa cells for 2 h with the PKC inhibitor
Ro31-8220, and then stimulated the cells with TNF or PMA
for 18 h. Western blot analysis revealed that TRAF1 induc-
tion by PMA can be considerably inhibited by 0.5 WM Ro31-
8220 (Fig. 3A). In contrast, TNF mediated induction of
TRAF1 was una¡ected by Ro31-8220. These results suggest
that in the case of TNF, TRAF1 induction is PKC independ-
ent. As we previously already demonstrated a role for p38
MAPK in TNF induced expression of IL-6 and granulocyte/
macrophage colony stimulating factor [19], we also analyzed
the role of this kinase in TRAF1 expression by pretreating
HeLa cells with the p38 MAPK inhibitor SB203580. However,
the latter did not a¡ect the TNF induced expression of
Fig. 1. TNF and PMA induce TRAF1 expression. A: 2U105 HeLa
cells were left untreated (control) or treated for 18 h with 1000 IU/
ml TNF, 7000 IU/ml IL-1 or 200 ng/ml PMA. 200 Wg total cellular
protein was analyzed by SDS-PAGE and immunoblot analysis with
anti-TRAF1 antibodies. B: IL-6 levels in the supernatant of the
cells that were treated as described in A were measured in an IL-6
bioassay. Results are representative for three independent experi-
ments.
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TRAF1 (data not shown), indicating that also p38 MAPK is
not involved in the upregulation of TRAF1 by TNF.
Because TNF is known to be a very potent activator of NF-
UB, we subsequently analyzed the role of this transcription
factor in TRAF1 expression by pretreating HeLa cells for
2 h with the proteasome inhibitor MG-132. The latter has
previously been shown to inhibit NF-UB activation by pre-
venting the degradation of the NF-UB inhibitory protein
IUB [22]. 20 WM MG-132 completely prevented the induction
of TRAF1 by TNF (Fig. 3B). A similar e¡ect could be ob-
tained with the NF-UB inhibitors BAY11-7085 and gliotoxin
([23,24]; data not shown). These results suggest a role for
TNF induced NF-UB activation in the upregulation of
TRAF1.
3.3. TRAF1 inhibits NF-UB dependent gene expression
TRAF1 di¡ers from the other members of the TRAF fam-
ily by the lack of an N-terminal ring ¢nger structure. This
domain was previously shown to be required for the NF-UB
activating potential of TRAF2 and TRAF6 in the TNF ini-
tiated or IL-1 initiated signalling pathway, respectively
[8,13,15]. Moreover, mutants of the latter proteins lacking
the N-terminal ring ¢nger structure can act as dominant neg-
ative inhibitors of NF-UB activation [3,13]. Therefore, we an-
alyzed whether overexpression of TRAF1 in HEK293T cells
was able to prevent TNF or IL-1 induced NF-UB activation.
Indeed, TRAF1 considerably decreased TNF and IL-1 in-
duced expression of a NF-UB dependent reporter gene (Fig.
4A). In contrast, overexpression of TRAF2 or TRAF6 did
not modulate the e¡ect of TNF or IL-1, but already activated
NF-UB as such. The latter can be explained by spontaneous
oligomerization of TRAF2 or TRAF6 upon overexpression,
which will also initiate signalling [15]. Coexpression of
TRAF1 also prevented NF-UB activation induced by
TRAF2 or TRAF6 (Fig. 4B), suggesting that TRAF1 inter-
feres with TRAF mediated signalling.
3.4. TRAF1 overexpression has no e¡ect on the binding of
TRAF2 with TRADD or RIP
TRAF2 physically interacts with the TNFR adapter pro-
teins TRADD and RIP, thereby linking the TNFR to the NF-
UB activation pathway. TRAF1 also interacts with TRADD
and RIP [3,4], but is unable to activate NF-UB. Moreover,
TRAF1 is able to form heterodimers with TRAF2 [6]. It is
therefore tempting to speculate that TRAF1 may sequester
TRAF2 and thereby negatively regulate NF-UB activation.
We therefore investigated whether overexpression of TRAF1
in HEK293T cells could prevent the TRAF2-RIP or TRAF2-
Fig. 2. Time kinetics of TRAF1 expression induced by TNF. 2U105
HeLa cells were treated with 1000 IU/ ml TNF for the indicated
times. Cells were harvested and 200 Wg total cellular protein was an-
alyzed by SDS-PAGE and immunoblot analysis with anti-TRAF1
antibodies. The arrowhead indicates the TRAF1 protein.
Fig. 3. E¡ect of PKC and proteasome inhibitors on induction of
TRAF1. A: 3U105 HeLa cells were left untreated (control) or pre-
treated for 2 h with the indicated concentrations of the PKC inhibi-
tor Ro31-8220, and subsequently stimulated with 1000 IU/ml TNF
or 200 ng/ml PMA. Cells were lysed 18 h later and 200 Wg total cel-
lular protein was analyzed by SDS-PAGE and immunoblot analysis
with anti-TRAF1 antibodies. B: 3U105 HeLa cells were left un-
treated (control) or treated for 2 h with 20 WM of the proteasome
inhibitor MG-132 prior to treatment with 1000 IU/ml TNF. Cells
were lysed 18 h later and 200 Wg total cellular protein was analyzed
by SDS-PAGE and immunoblot analysis with anti-TRAF1 antibod-
ies.
Fig. 4. Overexpression of TRAF1 inhibits NF-UB activation. A:
HEK293T cells transiently transfected with a NF-UB luciferase (luc)
reporter construct and a L-galactosidase (gal) expression vector were
stimulated for 6 h with TNF and IL-1 or left untreated, and subse-
quently luciferase activity was determined and normalized for L-ga-
lactosidase activity. B: HEK293T cells were transiently transfected
with a NF-UB luciferase reporter construct, a L-galactosidase expres-
sion vector, and speci¢c TRAF expression vectors as indicated.
Cells were analyzed 44 h later for luciferase and L-galactosidase ac-
tivity. Results shown are representative for three independent experi-
ments.
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TRADD interaction. However, TRAF1 coexpression had no
e¡ect on the coimmunoprecipitation of TRAF2 with RIP or
TRADD, respectively (Fig. 5). Although we cannot exclude
an e¡ect of TRAF1 on other protein interactions with
TRAF2, the above results make it unlikely that TRAF1 in-
terferes with NF-UB activation by competing with TRAF2 for
binding to TRADD or RIP.
4. Discussion
This study documents TRAF1 expression in response to
TNF, IL-1 or PMA, and describes the biological function of
TRAF1 in NF-UB signalling. We focussed our work on
TRAF1 because Northern blot analysis has previously dem-
onstrated that, unlike the other TRAF family members,
TRAF1 expression is restricted to spleen, lung and testis [6].
In addition, TRAF1 di¡ers from the other TRAFs by the lack
of an N-terminal ring ¢nger domain. Deletion of this domain
in other TRAFs leads to the generation of dominant negative
TRAF mutants, suggesting that the ring ¢nger domain is crit-
ical for TRAF mediated signalling. Moreover, a similar dom-
inant negative e¡ect has been demonstrated for a splice var-
iant of TRAF2, which contains an insert of seven amino acids
in the ring ¢nger structure [25], further demonstrating the
importance of the RING ¢nger in TRAF mediated signalling.
Although TRAF1 was identi¢ed as a protein that is recruited
to the TNFR2 in a heterodimeric complex with TRAF2 [6], its
biological role has remained largely unclear. TRAF1 seems to
be required for the recruitment of cellular inhibitor of apop-
tosis proteins and the zinc ¢nger protein A20 to TNFR2
[26,27]. Finally, transgenic TRAF1 expression was shown to
inhibit antigen induced cell death of CD8 T lymphocytes
[28], as well as TNF induced apoptosis [29].
Our results demonstrate that overexpression of TRAF1
completely prevents TNF and IL-1 induced NF-UB activation
in HEK293T cells. Moreover, we also show that TRAF1 ex-
pression can be induced by stimulation of cells with TNF or
PMA. All together, these results suggest that induction of
TRAF1 functions to downregulate NF-UB activation in re-
sponse to TNF or IL-1. While this article was under revision,
it was shown in an independent study that TRAF1 overex-
pression can induce a two-fold increase of TNF induced NF-
UB activation in HeLa cells [30]. At this moment, the reason
for these contrasting results is still unclear. However, it should
be mentioned that in the other study, transfections were per-
formed with rather high concentrations of a TRAF1 expres-
sion plasmid (10 Wg versus 750 ng in our study). Alternatively,
cell type dependent e¡ects might be involved. In this context,
we were also unable to detect an e¡ect of IL-1 on TRAF1
expression in HeLa or PC60 cells, whereas IL-1 was shown in
the other study to increase TRAF1 expression in SV80 cells
[30] (although this was only demonstrated at the mRNA lev-
el). Similarly, we and others were unable to detect an e¡ect of
TNF on TRAF2 expression in several cell lines [30], whereas
Wang and coworkers previously reported a TNF induced up-
regulation of TRAF2 in HT1080 ¢brosarcoma cells [29].
The TRAF1 gene was recently mapped and shown to con-
tain binding sites for AP-1, CREB/ATF, and NF-UB [31].
Transfection of cells with an IUB-K super-repressor of NF-
UB [19], as well as mutation analysis of TRAF1 gene pro-
moter luciferase constructs [30], has shown the functional im-
portance of the NF-UB elements. Our observations with chem-
ical inhibitors of the NF-UB activation pathway further
support the role of NF-UB in TRAF1 expression. However,
because TNF as well as IL-1 activate NF-UB in several cell
lines, including HeLa cells (our own unpublished observa-
tions), the di¡erential e¡ect of both cytokines on TRAF1
expression in HeLa cells cannot be explained by a di¡erence
in NF-UB activation. Further studies will be required to point
this out in more detail.
The mechanism by which TRAF1 interferes with TNF and
IL-1 induced NF-UB activation is still unclear. Because
TRAF1 can bind via its C-terminal TRAF domain with sev-
eral signalling molecules that are involved in NF-UB activa-
tion by TNF and IL-1 [3,4,32], it might prevent the interac-
tion of these signalling molecules with upstream or
downstream e¡ector molecules of the NF-UB pathway. How-
ever, we were unable to demonstrate any e¡ect of TRAF1
overexpression on the binding of TRAF2 with either TRADD
or RIP, making the former hypothesis rather unlikely. Re-
cently, TRAF1 has been shown to stabilize the expression
of TRAF2A, which is a splice variant of TRAF2 that has
been characterized as a natural inhibitor of TRAF2 mediated
NF-UB activation [25]. Although the above observation can
explain the e¡ect of TRAF1 on TNF induced NF-UB activa-
tion, it fails to explain the inhibitory e¡ect of TRAF1 on IL-1
induced NF-UB activation because the latter has been shown
to be TRAF2A insensitive. A third and most likely explana-
tion is that TRAF1 is responsible for the recruitment of cel-
lular inhibitors of NF-UB activation to the TNF or IL-1 re-
ceptor complex. In this context, the zinc ¢nger protein A20
has previously been shown to associate speci¢cally with
TRAF1-TRAF2 heterodimers [27], and to prevent NF-UB ac-
tivation at the level of TRAF2 [33]. Experiments to verify
whether TRAF1 recruits A20 or other proteins into the
TNFR complex are under way.
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Fig. 5. TRAF1 has no e¡ect on the coimmunoprecipitation of
TRAF2 with RIP or TRADD. HEK293T cells were transiently
transfected with expression plasmids for TRAF1, TRAF2, E-tagged
TRADD (TRADDE) and/or E-tagged RIP (RIPE) as indicated. The
next day, TRADDE (A) and RIPE (B) were immunoprecipitated
with anti-E-tag antibodies and coimmunoprecipitation of TRAF2
was detected via Western blot analysis with anti-TRAF2 antibodies.
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